This page shows the latest trial failures news and features for those working in and with pharma, biotech and healthcare.
combination. MET is known as a resistance mechanism for EGFR-positive NSCLC, and Merck also has a trial on the go of tepotinib plus Tagrisso in this setting. ... ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of
Looking for mid-stage trial success in field littered with failures. Following in Amarin’s footsteps, Dutch biotech Northsea Therapeutics has successfully raised $40m (36m) for the development of a fish ... French pharma Genfit also has a candidate
The data from the phase 3 JAVELIN Bladder 100 trial has confirmed that Bavencio statistically improves survival in its approved patient population. ... The extension into the earlier indication in bladder cancer is vital for Bavencio, which has been
Data from the active treatment phase of STRIVE looked at efficacy and safety of Aimovig (70 and 140 mg) in episodic migraine patients with prior preventive treatment failures. ... Trial data shows that 55% of patients on Aimovig 140 mg experienced at
The biotech’s first phase 2 trial recruited patients with VHL mutations and is testing PT2977 as a monotherapy, while a second all-comer metastatic RCC trial is pairing the drug ... which has recently seen some late-stage trial failures involving
PR022 did not show the desired effect in this trial,” said Alex Martin, the biotech’s CEO. ... considerably after the twin trial failures.
More from news
Approximately 5 fully matching, plus 30 partially matching documents found.
major trial failures meaning the company was looking unlikely to fill the void created by patent expiries of key drugs.
Smaller entities such as Isu Abxis are listed companies whose stock prices and financial stability are especially vulnerable to trial failures. ... Some companies already have their biobetter pipelines in clinical trial stage.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
a series of clinical trial failures leading to the departure of AZ's previous CEO Brennan in April, 2012.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
However, the learnings from these ‘failures’ have paved the way for the robust pipeline of treatments that could potentially be coming to market in the next five years. ... A recent article by BLH Consultant David Cooney explored the bleak
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...